Hepatology News and Research

RSS

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Early data from phase I trials of an HCV vaccine presented today at the International Liver CongressTM show encouraging results, with high immunogenicity and good safety profile.

2 Apr 2011

Donation after cardiac death may broaden the scope of organ donor selection

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

1 Apr 2011

New findings from two modeling studies can help reduce HCV-related deaths in Europe

New findings from two modeling studies presented at the International Liver Congress support the call to action from medical experts and patients in relation to the challenge health inequalities represent in the diagnosis and access to HCV treatment.

1 Apr 2011

Study finds AKIN criteria effective in cirrhosis detection

The first clinical study investigating the use of the AKIN criteria in cirrhosis has shown significant benefits that have the potential to change future diagnosis, according to results from a Spanish study presented today at the International Liver Congress.

1 Apr 2011

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC.

1 Apr 2011

Study confirms D-penicillamine and trientine effective against Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

31 Mar 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

DSP, Intercept enter license agreement for OCA

Dainippon Sumitomo Pharma Co, Ltd. and Intercept Pharmaceuticals, Inc. today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid.

30 Mar 2011

DISCUSS survey findings highlight need to prioritize GERD dialogue

According to findings from the new nationwide DISCUSS Survey, many people surveyed report that their gastroesophageal reflux disease and/or persistent heartburn symptoms significantly disrupt their lives.

24 Mar 2011

Researchers discover novel gene regulation mechanism that contributes to HCC development

Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma.

23 Mar 2011

Cognitive impairment may not be fully reversible in patients with liver disease: Study

There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

19 Mar 2011

Study: Dried plums more safe, effective than psyllium to treat constipation

Given their palatability, tolerability and availability, dried plums should be considered the initial approach to the management of mild to moderate constipation in the general population, according to results of a randomized clinical trial recently published in Alimentary Pharmacology and Therapeutics.

16 Mar 2011

Conservative approach with endoscopic techniques can resolve colonic perforation

Colonoscopy is considered a safe procedure, although complications can occur. The most dreaded of these is iatrogenic perforation. The literature reports perforation rates of 0.03%-0.8% for diagnostic procedures, and a rate of 0.15%-3% for therapeutic procedures.

16 Mar 2011

Hepatology News and Research

Further Reading

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Donation after cardiac death may broaden the scope of organ donor selection

New findings from two modeling studies can help reduce HCV-related deaths in Europe

Study finds AKIN criteria effective in cirrhosis detection

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Study confirms D-penicillamine and trientine effective against Wilson disease

New data confirms antiviral activity of fluvastatin in patients with HCV

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Three-drug cocktail more effective against hepatitis C virus

DSP, Intercept enter license agreement for OCA

DISCUSS survey findings highlight need to prioritize GERD dialogue

Researchers discover novel gene regulation mechanism that contributes to HCC development

Cognitive impairment may not be fully reversible in patients with liver disease: Study

Study: Dried plums more safe, effective than psyllium to treat constipation

Conservative approach with endoscopic techniques can resolve colonic perforation

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News